DNALite Therapeutics is an early-stage preclinical biotechnology company committed to bringing the next generation of drugs to the gastrointestinal tract. It develops oral lipid nanoparticle technology to deliver mRNA and pDNA into the intestine using the oral route of administration. Its drug aims to use the intestinal tract to secrete proteins